Optic Nerve Injuries

PORT WASHINGTON, N.Y., April 15, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, is linked to the active ingredient, semaglutide, in Ozempic and Wegovy. The case is now pending in the Superior Court of New Jersey, Middlesex County. Parker Waichman LLP is urging individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact the firm for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fighting for Victims Nationwide "NAION is a devastating, permanent eye injury. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

National Law Firm Filed One of the First Eye Injury Cases against Novo Nordisk in the Superior Court of New Jersey, Middlesex County PORT WASHINGTON, N.Y., April 14, 2025 /PRNewswire/ -- Parker Waichman LLP, a nationally recognized law firm dedicated to representing victims of defective drugs and devices, recently filed a lawsuit against Novo Nordisk on behalf of a New Jersey based Plaintiff diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION). NAION, a debilitating eye condition, is linked to the active ingredient, semaglutide, in Ozempic and Wegovy. The case is pending in the Superior Court of New Jersey, Middlesex County. The firm is urging individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact Parker Waichman LLP for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fighting for Victims Nationwide "NAION is a devastating, permanent eye injury. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic) and NAION. Despite this evidence, Novo Nordisk continues to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable. " said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic or Wegovy. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic or Wegovy, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Parker Waichman LLP Phone: 1-800-YOUR-LAWYER (1-800-968-7529) Website: SOURCE Parker Waichman LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MONDAY, Feb. 10, 2025 -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye trouble, according to a new small study. The study reviewed the cases of nine people who developed sight-robbing issues, such as dysfunction in blood vessels around the eye's optic nerve, after taking a GLP-1 . “We’re trying to elucidate if being on these drugs can increase your risk,” said study co-author Dr. Norah Lincoff . She's a neuro-ophthalmologist and professor of neurology at the University at Buffalo. The study, published recently in JAMA Opthalmology , focused on nine patients, all in their 50s or 60s, who were taking GLP-1s such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound). Seven of the nine patients developed a condition known as nonarteritic anterior ischemic optic neuropathy (NAION). This occurs when blood vessels fail to supply enough blood to the optic nerve, which is crucial for sight. In NAION, damage to the nerve can lead to a sudden and permanent partial loss of vision. Lead study author Dr. Bradley Katz , of the John A. Moran Eye Center at University of Utah Health in Salt Lake City, first noted the issue in a patient who experienced a sudden and painless loss of vision in one eye after starting seamglutide. The patient briefly halted use of the drug, but when they resumed use, vision loss occurred in the other eye. Alarmed, Katz used a listserve to ask other ophthalmologists if they'd noticed anything similar in their patients. That query resulted in the nine case reports outlined in the new study. While seven of the nine patients appeared to have NAION, one other patient had developed a "maculopathy"-- a blind spot -- in their vision after taking a GLP-1. Another developed papillitis, an inflammation of the head of the optic nerve. The researchers point out that very rare cases of NAION have previously been linked to the use of erectile dysfunction meds or drugs used to ease irregular heartbeats. On the other hand, common chronic illnesses, such as diabetes, heart disease or obesity, have also been known to help bring on vision trouble. The authors note that all nine patients were taking a GLP-1 because they were battling obesity and/or diabetes. So it's unclear if the vision troubles were linked to use of a GLP-1 or one of the underlying medical conditions the patients may have had, the researchers said. It's even possible that, in rare cases, sudden, steep and healthy reductions in blood sugar levels that can come with GLP-1 use might make a person's eyes more vulnerable, Lincoff said. “So are these drugs increasing the risk for an episode of visual loss?” Lincoff asked. “The message to the patient is that we are still investigating if these drugs put them at higher risk of ischemic optic nerve damage." As for doctors, she offered this advice: "If a patient on one of these medications calls you and says that there is blurring or vision loss, have them see their ophthalmologist as soon as possible. Don’t wait. Maybe it’s a fluctuation in glucose or it could be something more serious.” In the meantime, anyone already on a GLP-1 shouldn't panic, the researchers said. Cases of vision trouble linked to the drugs are very rare, but if issues do arise, check with your doctor. “We have other ways to control diabetes and weight loss,” Lincoff concluded. “There are many options for patients.” Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.